Real-world Data Collection on Frail and Previously Treated Patients with Large B-Cell Lymphoma Focusing on Those Unsuitable for Standard Treatments or with Relapsed Disease

What this Trial Is About

Researchers are studying large B-cell lymphoma LBCL, a cancer affecting the lymphatic system where certain white blood cells grow uncontrollably. This research focuses on patients who cannot tolerate standard full-dose chemo-immunotherapy treatments due to frailty or who have relapsed or not responded to initial treatments. The goal is to collect real-world data on how these patients are managed and their outcomes to improve understanding and future care for LBCL. The study observes two groups those with LBCL who need treatment but are unsuitable for standard full-dose therapies, and those with relapsed or refractory LBCL after prior treatment. The study does not test new drugs but gathers information from patients receiving various treatments in routine care. Retrospective data from patients who started treatment within six months before enrollment may also be included. Participants will provide information through medical records and follow-up over time. Researchers will monitor progression-free survival at 12 months as the primary outcome. The study is observational, so no specific treatments are assigned, but data on treatments and responses will be collected to help guide future research and improve care. Enrollment begins in October 2024 and continues through 2028.

A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma